Telmisartan protects against microvascular dysfunction during myocardial ischemia/reperfusion injury by activation of peroxisome proliferator-activated receptor gamma

[1] Antman EM(2008)2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 51 210-247

[2] Hand M(2006)Long-term outcome of primary percutaneous coronary intervention vs prehospital and in-hospital thrombolysis for patients with ST-elevation myocardial infarction JAMA 296 1749-1756

[3] Armstrong PW(2001)The coronary no-reflow phenomenon: a review of mechanisms and therapies Eur Heart J 22 729-739

[4] Bates ER(2008)The diagnosis and treatment of the no-reflow phenomenon in patients with myocardial infarction undergoing percutaneous coronary intervention Exp Clin Cardiol 13 121-128

[5] Green LA(1995)Features and outcome of no-reflow after percutaneous coronary intervention Am J Cardiol 75 778-782

[6] Halasyamani LK(2002)Plaque gruel of atheromatous coronary lesion may contribute to the no-reflow phenomenon in patients with acute coronary syndrome Circulation 106 1672-1677

[7] Hochman JS(2000)Recognition of the importance of embolization in atherosclerotic vascular disease Circulation 101 570-580

[8] Krumholz HM(1996)Alternation in the coronary blood flow velocity pattern in patients with no reflow and reperfused acute myocardial infarction Circulation 94 1269-1275

[9] Lamas GA(2004)Optimal therapeutic strategies in the setting of post-infarct no reflow: the need for a pathogenetic classification Heart 90 123-125

[10] Mullany CJ(2006)AT1 receptor blockade prevents microvascular dysfunction induced by ischemia/reperfusion injury J Atheroscler Thromb 13 231-239

[1] Antman EM(2008)2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 51 210-247

[2] Hand M(2006)Long-term outcome of primary percutaneous coronary intervention vs prehospital and in-hospital thrombolysis for patients with ST-elevation myocardial infarction JAMA 296 1749-1756

[3] Armstrong PW(2001)The coronary no-reflow phenomenon: a review of mechanisms and therapies Eur Heart J 22 729-739

[4] Bates ER(2008)The diagnosis and treatment of the no-reflow phenomenon in patients with myocardial infarction undergoing percutaneous coronary intervention Exp Clin Cardiol 13 121-128

[5] Green LA(1995)Features and outcome of no-reflow after percutaneous coronary intervention Am J Cardiol 75 778-782

[6] Halasyamani LK(2002)Plaque gruel of atheromatous coronary lesion may contribute to the no-reflow phenomenon in patients with acute coronary syndrome Circulation 106 1672-1677

[7] Hochman JS(2000)Recognition of the importance of embolization in atherosclerotic vascular disease Circulation 101 570-580

[8] Krumholz HM(1996)Alternation in the coronary blood flow velocity pattern in patients with no reflow and reperfused acute myocardial infarction Circulation 94 1269-1275

[9] Lamas GA(2004)Optimal therapeutic strategies in the setting of post-infarct no reflow: the need for a pathogenetic classification Heart 90 123-125

[10] Mullany CJ(2006)AT1 receptor blockade prevents microvascular dysfunction induced by ischemia/reperfusion injury J Atheroscler Thromb 13 231-239